KYNB
Kyntra Bio, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$28.00M
P/E Ratio
—
EPS
$-14.28
Beta
0.90
52W High
$12.60
52W Low
$4.85
50-Day MA
$7.41
200-Day MA
$8.84
Dividend Yield
—
Profit Margin
2849.00%
Forward P/E
61.35
PEG Ratio
—
About Kyntra Bio, Inc.
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is headquartered in San Francisco, California.
Fundamentals
| Revenue (TTM) | $6.44M |
| Gross Profit (TTM) | $-17.63M |
| EBITDA | $-44.59M |
| Operating Margin | -1059.00% |
| Return on Equity | 0.00% |
| Return on Assets | -17.00% |
| Revenue/Share (TTM) | $1.59 |
| Book Value | $-7.42 |
| Price-to-Book | 80.40 |
| Price-to-Sales (TTM) | 4.35 |
| EV/Revenue | 12.23 |
| EV/EBITDA | 44.15 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -59.30% |
| Shares Outstanding | $4.05M |
| Float | $3.56M |
| % Insiders | 1.57% |
| % Institutions | 28.45% |
Analyst Ratings
Consensus ($43.00 target)
1
Buy1
HoldData last updated: 4/8/2026